Expression of MSP58 in hepatocellular carcinoma

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Zhong, Ming ^a   Zhang, Xi ^b   Li, Bing ^b   Chen, Chang Sheng ^c   Ji, Gen Lin ^b   Li, Shi Xing ^d   Bi, Dan Qing ^e   Zhao, Qing Chuan ^b   Shi, Hai ^b  

^a FIRST PEOPLE S HOSPITAL OF YUNNAN PROVINCE   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d Department of General Surgery   (China)

^e KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; MSP58; Prognosis; UICC

Indexed keywords

MSP58 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; MCRS1 PROTEIN, HUMAN; NUCLEAR PROTEIN; RNA BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; GENETIC DIFFERENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANK SUM TEST; SURVIVAL TIME; TISSUE SECTION; TUMOR VOLUME; WILCOXON SIGNED RANKS TEST; ANIMAL; BIOSYNTHESIS; CELL STRAIN HEPG2; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NUDE MOUSE; SURVIVAL RATE;

ADULT; AGED; ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NUCLEAR PROTEINS; RNA-BINDING PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84875080008     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0539-2     Document Type: Article

References (32)

1. Luk JM, Liu AM. Proteomics of hepatocellular carcinoma in Chinese patients. OMICS. 2011;15(5):261-6.
2. Block T, Mehta AS, London WT. Hepatocellular carcinoma of the liver. Cancer Biomark. 2010;9(1-6):375-83.
3. Washburn K, Halff G. Hepatocellular carcinoma and liver transplantation. Curr Opin Organ Transplant. 2011;16(3):297-300.
4. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology. 2011;81(Suppl 1):50-5.
5. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43-58.
6. Yu L, Dai Z, Wang Z, Fan J, Zhou J. Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy. Oncology. 2011;81(Suppl 1):116-22.
7. Masuda T, Miyoshi E. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clin Chem Lab Med. 2011;49(6):959-66.
8. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292-301.
9. Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol. 2011;46(3):289-96.
10. Ren Y, Busch RK, Perlaky L, Busch H. The 58-kDa microspherule protein (MSP58), a nucleolar protein, interacts with nucleolar protein p120. Eur J Biochem. 1998;253(3):734-42.
11. Lin DY, Shih HM. Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration. J Biol Chem. 2002;277(28):25446-56.
12. Bader AG, Schneider ML, Bister K, Hartl M. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1). Oncogene. 2001;20(51):7524-35.
13. Du X, Wang Q, Hirohashi Y, Greene MI. DIPA, which can localize to the centrosome, associates with p78/MCRS1/MSP58 and acts as a repressor of gene transcription. Exp Mol Pathol. 2006;81(3):184-90.
14. Ivanova AV, Ivanov SV, Lerman ML. Association, mutual stabilization, and transcriptional activity of the STRA13 and MSP58 proteins. Cell Mol Life Sci. 2005;62(4):471-84.
15. Karagiannidis AI, Bader AG, Hartl M. Bister K.TOJ3, a v-jun target with intrinsic oncogenic potential, is directly regulated by Jun via a novel AP-1 binding motif. Virology. 2008;378(2):371-6.
16. Okumura K, Zhao M, DePinho RA, Furnari FB, Cavenee WK. PTEN: a novel anti-oncogenic function independent of phosphatase activity. Cell Cycle. 2005;4(4):540-2.
17. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA. 2005;102(8):2703-6.
18. Lin W, Zhang J, Zhang J, et al. RNAi-mediated inhibition of MSP58 decreases tumour growth, migration and invasion in a human glioma cell line. J Cell Mol Med. 2009;13(11-12):4608-22.
19. Shi H, Chen S, Jin H, et al. Downregulation of MSP58 inhibits growth of human colorectal cancer cells via regulation of the cyclin D1-cyclin-dependent kinase 4-p21 pathway. Cancer Sci. 2009;100(9):1585-90.
20. Shi H, Li N, Li S, et al. Expression of NDRG2 in esophageal squamous cell carcinoma. Cancer Sci. 2010;101(5):1292-9.
21. Shi H, Zhou Y, Liu H, et al. Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis. BMC Cancer. 2010;10:477.
22. Xu XM, Yuan GJ, Deng JJ, et al. Inhibition of 12-lipoxygenase reduces proliferation and induces apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Hepatobiliary Pancreat Dis Int. 2012;11(2):193-202.
23. Zhao JJ, Pan K, Li JJ, et al. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma. PLoS ONE. 2011;6(10):e26608.
24. Zhang J, Liu J, Li X, et al. The physical and functional interaction of NDRG2 with MSP58 in cells. Biochem Biophys Res Commun. 2007;352(1):6-11.
25. Wu JL, Lin YS, Yang CC, et al. MCRS2 represses the transactivation activities of Nrf1. BMC Cell Biol. 2009;10:9.
26. Choi SC, Yoon SR, Park YP, et al. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med. 2007;39(6):705-14.
27. Piepoli A, Cotugno R, Merla G, et al. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics. 2009;2:11.
28. Kim YJ, Yoon SY, Kim JT, et al. NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis. 2009;30(4):598-605.
29. Lorentzen A, Vogel LK, Lewinsky RH, et al. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer. 2007;7:192.
30. Ventura-Holman T, Mamoon A, Subauste MC, Subauste JS. The effect of oncoprotein v-erbA on thyroid hormone-regulated genes in hepatocytes and their potential role in hepatocellular carcinoma. Mol Biol Rep. 2011;38(2):1137-44.
31. Lee DC, Kang YK, Kim WH, et al. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res. 2008;68(11):4210-20.
32. Zhao H, Zhang J, Lu J, et al. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer. 2008;8:303.